Can Diabetes Drugs Protect Newborn Brains From Oxygen Deprivation?
GLP-1 drugs exendin-4 and semaglutide reduced brain damage and improved survival in newborn mice after oxygen deprivation injury.
Quick Facts
What This Study Found
Both exendin-4 and semaglutide improved outcomes when given right after brain injury in newborn mice. The drugs reduced the size of the damaged brain area, increased survival rates, and improved locomotor function in both short-term and long-term assessments.
The mechanism involved upregulation of the PI3K/AKT signaling pathway (a cell survival pathway) and increased cAMP levels (a molecule that helps cells communicate). The drugs also reduced inflammation after oxygen-glucose deprivation in brain cells.
Key Numbers
- Incidence of HIE: 1.5 per 1,000 live births globally
- Both drugs improved neuropathology scores, survival, and motor function
- PI3K/AKT pathway upregulated
- cAMP levels increased
- Specific effect sizes not reported in abstract
How They Did This
Researchers surgically induced hypoxic-ischemic brain injury in 10-day-old mice by blocking the middle cerebral artery. They then gave the mice exendin-4 or semaglutide systemically right after the injury. They measured brain damage using tissue staining, tracked survival, and tested movement abilities. They also studied the mechanism in brain cells deprived of oxygen and glucose in the lab.
Why This Research Matters
Hypoxic-ischemic encephalopathy (HIE) happens when a baby's brain does not get enough blood and oxygen during birth. It affects about 1.5 per 1,000 live births worldwide and can cause death or severe brain damage. The only current treatment is cooling the baby's body (therapeutic hypothermia). If GLP-1 drugs could add neuroprotection, it would be a major advance.
The Bigger Picture
The only current treatment for birth-related brain injury is body cooling. If GLP-1 drugs could provide additional neuroprotection, it would be a major advance for a condition that kills or severely disables thousands of newborns yearly.
What This Study Doesn't Tell Us
This was tested in mice, not people. Neonatal mouse brain injury is an imperfect model for human HIE. The drugs were given immediately after injury, which may not reflect realistic clinical timing. No long-term developmental or cognitive outcomes were reported. The leap from preclinical mouse data to neonatal clinical use is enormous.
Questions This Raises
- ?Can these results be replicated in larger animal models?
- ?Would GLP-1 drugs add benefit on top of therapeutic hypothermia?
- ?Is the treatment window realistic for clinical use?
Trust & Context
- Key Stat:
- 1.5 per 1,000 births Hypoxic-ischemic encephalopathy affects roughly 1.5 in every 1,000 babies born worldwide
- Evidence Grade:
- Rated preliminary: promising animal study results, but mouse brain injury is an imperfect model for human birth asphyxia, and the drugs were given immediately after injury.
- Study Age:
- Published in 2024. This is early-stage preclinical research; human trials have not yet been conducted for this use.
- Original Title:
- Diabetes drugs activate neuroprotective pathways in models of neonatal hypoxic-ischemic encephalopathy.
- Published In:
- EMBO molecular medicine, 16(6), 1284-1309 (2024)
- Authors:
- Poupon-Bejuit, Laura, Geard, Amy, Millicheap, Nathan, Rocha-Ferreira, Eridan, Hagberg, Henrik, Thornton, Claire, Rahim, Ahad A
- Database ID:
- RPEP-09084
Evidence Hierarchy
Frequently Asked Questions
Could semaglutide be used for brain injury in babies?
It showed promise in mice, but this is very early research. Major steps including larger animal studies and human safety trials would be needed first.
How do GLP-1 drugs protect the brain?
They activate the PI3K/AKT cell survival pathway and increase cAMP levels, which help cells resist damage from oxygen deprivation.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09084APA
Poupon-Bejuit, Laura; Geard, Amy; Millicheap, Nathan; Rocha-Ferreira, Eridan; Hagberg, Henrik; Thornton, Claire; Rahim, Ahad A. (2024). Diabetes drugs activate neuroprotective pathways in models of neonatal hypoxic-ischemic encephalopathy.. EMBO molecular medicine, 16(6), 1284-1309. https://doi.org/10.1038/s44321-024-00079-1
MLA
Poupon-Bejuit, Laura, et al. "Diabetes drugs activate neuroprotective pathways in models of neonatal hypoxic-ischemic encephalopathy.." EMBO molecular medicine, 2024. https://doi.org/10.1038/s44321-024-00079-1
RethinkPeptides
RethinkPeptides Research Database. "Diabetes drugs activate neuroprotective pathways in models o..." RPEP-09084. Retrieved from https://rethinkpeptides.com/research/poupon-bejuit-2024-diabetes-drugs-activate-neuroprotective
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.